ArticleBiosafety and health2022
Biobanking in LMIC settings for infectious diseases: Challenges and enablers.
Article in Biosafety and health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It carries an expression of concern. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Precision medicine in low-income settings and small island developing states.Nature reviews. Endocrinology · 2026Review
- Biobanking of vector-borne viruses in the Philippines: basic principles, best practices, and challenges.Scientific reports · 2026Article
- Streamlining protocols for the establishment of a physical biobank of respiratory viruses in the Philippines.Journal of translational medicine · 2026Article
- Vietnam biobanking feasibility study: An overview of biobanking landscape, infrastructure, and capacity.AIMS public health · 2026Article
- Digitalisation of medicine in LMICs (sub-Saharan Africa): enablers, barriers, and funding strategies for sustainable health systems.Frontiers in public health · 2026Review
- A new dawn: Vitalising translational oncology research in Africa with the help of advanced cell culture models.Translational oncology · 2025Article
- Assessment of biobank awareness among medical students in Iran.Journal of community genetics · 2025Article
- Development of biobanking infrastructure in Armenia: opportunities and challenges.Frontiers in public health · 2025Review
- Development of a Plasmodium vivax biobank for functional ex vivo assays.Malaria journal · 2023Article
Corrections and comments
- Expression of concern
Authors and funding
3 authors.
Funding
Abstract
Biobanking facilities are well established in high-income settings, where substantial funding has been invested in infrastructure. In contrast, such facilities are much less developed in resource-restricted settings. However, low-and middle-income countries (LMICs) still face a disproportionately high infectious diseases burden. Thus, the further development of infrastructure facilities, including biobanks is warranted as an important component of this unfolding clinical research environment. This perspective manuscript summarises the challenges and enablers for biobanking in LMICs, with a particular focus on infectious diseases, incorporating some of the lessons learned from the recent coronavirus disease 2019 (COVID-19) pandemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.